what if

an employee benefit could be life-changing

Beating cancer starts with knowing you have it

The earlier cancer is found, the higher the chance everyone wins: likely better outcomes for those finding it and greater peace of mind for those without it. Offering GalleriTM, a multi-cancer early detection test, was found to encourage employees to join, stay, and understand they’re part of a workplace that truly cares.1

Employees say the Galleri test is the #1 ranked health benefit

Most cancers are not tested for today

Cancer is the most feared disease.2 Today, routine cancer screenings fail to detect 72% of invasive cancers.3 As a result, these cancers go undetected until they have progressed to an advanced stage where outcomes are often poor and treatment costs are high.4 – 7

72% of invasive cancers do not have screening tests

Introducing the Galleri test

The Galleri test is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older.

With the Galleri test, employees could receive the benefits of early detection of multiple cancers through a simple blood draw.

50+ cancer types detected

including cancers employees aren’t routinely screened for today9,10

0.5% false-positive rate

to help minimize unnecessary medical procedures9

89% accuracy

in predicting the location of the cancer, directing diagnostic workup9

The Galleri test is supported by large clinical studies.

The Galleri test is designed to integrate seamlessly to fit your needs 

We offer a flexible partnership model that is customized to your needs. 
Our efforts towards seamless integration will provide surround-sound marketing campaigns to drive enrollment, and wraparound services, including telemedicine consultations and support services, to ensure a positive experience.

1

Eligibility verification + test ordering through convenient online portal

2

Kit delivery + blood draw at home or lab

3

Return of results within 10 business days + support services

Contact us to learn more

Important safety information

The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests. Results should be interpreted by a healthcare provider. A Cancer Signal Not Detected” result does not rule out cancer. A Cancer Signal Detected” result requires confirmatory diagnostic evaluation (e.g. imaging), and if cancer is not confirmed, it may not be present, may not be detectable by diagnostic follow-up testing or may be located in a different part of the body. False-positive and false-negative test results do occur. Rx only.

Laboratory / test information

The GRAIL laboratory is CLIA-certified and CAP-accredited. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by FDA. The GRAIL laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is for clinical purposes. 

  1. Market research data on file 2020. Study demographics included 314 respondents, age 40+, who were employed full-time at larger organizations.
  2. Vrinten C, McGregor LM, Heinrich M, von Wagner C, Waller J, Wardle J, Black GB. What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population. Psycho-Oncology. 2017 Aug;26(8):1070 – 1079.
  3. Screening includes methods with USPSTF A or B rating. SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006 – 2015.
  4. Surveillance, Epidemiology, and End Results (SEER) Program (www​.seer​.can​cer​.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. Early/​Localized” includes invasive localized tumors that have not spread beyond organ of origin. Late/​Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
  5. Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer.
  6. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr Canc Netw. 2018;16(4):402 – 10.
  7. DaCosta Byfield S, Nash Smyth E, Mytelka D, et al. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. J Med Econ. 2013;16(12):1379 – 86.
  8. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. [updated 2020 Jan 13; cited 2021 Feb 18]. Available from: https://​www​.can​cer​.org/​c​a​n​c​e​r​/​c​a​n​c​e​r​-​b​a​s​i​c​s​/​l​i​f​e​t​i​m​e​-​p​r​o​b​a​b​i​l​i​t​y​-​o​f​-​d​e​v​e​l​o​p​i​n​g​-​o​r​-​d​y​i​n​g​-​f​r​o​m​-​c​a​n​c​e​r​.html
  9. Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
  10. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.
CHAT